Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma

This study is testing a personalized immunotherapy approach for people newly diagnosed with early-stage but unfavorable classical Hodgkin lymphoma — a cancer of the lymph system — to see if tailoring treatment based on early response leads to better outcomes. **You may be eligible if:** - You are between 18 and 60 years old (or 61+ if your overall health allows the standard treatment regimen) - You have just been diagnosed with classical Hodgkin lymphoma for the first time - Your disease is early-stage but considered high-risk because of factors like a large mass in the chest, spread outside lymph nodes, an elevated inflammation marker, or involvement of 3 or more lymph node areas **You may NOT be eligible if:** - You have a type of lymphoma called nodular lymphocyte-predominant Hodgkin lymphoma or grey-zone lymphoma - Your lymphoma has spread to the brain or spinal cord Talk to your doctor to see if this trial is right for you.